Loading...
Loading...
Browse all stories on DeepNewz
VisitGlobal adoption of Imdelltra as standard treatment by end of 2024
Adopted in over 20 countries • 25%
Adopted in 10-20 countries • 25%
Adopted in less than 10 countries • 25%
Not adopted as standard treatment • 25%
Health authority endorsements and adoption reports in multiple countries
Amgen's Imdelltra Receives Accelerated FDA Approval for Most Deadly Form of Lung Cancer in Landmark Decision
May 16, 2024, 08:06 PM
Amgen has received accelerated approval from the U.S. Food and Drug Administration (FDA) for its new drug, Imdelltra (tarlatamab), designed to treat adult patients with advanced small cell lung cancer (SCLC). This approval is significant as it targets a particularly aggressive and most deadly form of lung cancer that has worsened despite chemotherapy. Imdelltra is a DLL3-targeting bispecific T-cell engager and is the first BiTE® therapy for extensive-stage small cell lung cancer (ES-SCLC). The FDA approval, noted on the FDA website, is considered a landmark achievement in the evolution of small cell lung cancer care. The drug has shown promise in clinical trials by reducing tumor growth and extending patients' lives. It comes with a boxed warning for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). It is to be used only by patients who have exhausted all other options and have a life expectancy of four to five months.
View original story
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Approved in EU • 25%
Approved in Asia • 25%
Approved in LATAM • 25%
Not approved in other regions • 25%
EU only • 25%
UK only • 25%
Japan only • 25%
Multiple regions including EU, UK, and Japan • 25%
<10% • 25%
10%-25% • 25%
26%-50% • 25%
>50% • 25%
Widely adopted in over 50 countries • 25%
Adopted in 20-50 countries • 25%
Adopted in less than 20 countries • 25%
Not adopted widely • 25%
Top performer • 33%
Average performer • 34%
Underperformer • 33%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
No further action • 33%
Additional warnings issued • 33%
Restriction on use broadened • 33%
Increase by less than 5% • 25%
Increase by 5% to 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Widespread adoption in multiple continents • 25%
Adopted in Europe only • 25%
Adopted in North America only • 25%
No significant adoption • 25%
Stock price increases by over 20% • 33%
Stock price increases by less than 10% • 34%
Stock price increases by 10-20% • 33%